Evaluation of the HAM-D17 following eszopiclone treatment in patients with insomnia co-morbid with major depressive disorder or generalized anxiety disorder

被引：0

作者：

Fava, M. ^{[1
]}

Pollack, M. ^{[1
]}

Montgomery, S. ^{[2
]}

Wessel, T. ^{[3
]}

Amato, D. ^{[3
]}

Krystal, A. ^{[4
]}

Hayduk, R. ^{[5
]}

McCall, W. V. ^{[6
]}

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Imperial Coll Med, London, England

[3] Sepracor Inc, Marlborough, MA USA

[4] Duke Univ, Ctr Med, Durham, NC USA

[5] Quintiles Inc, San Diego, CA USA

[6] Wake Forest Univ Hlth Sci, Winston Salem, NC USA

来源：

EUROPEAN PSYCHIATRY | 2008年 / 23卷

关键词：

D O I：

10.1016/j.eurpsy.2008.01.1247

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

引用

页码：S360 / S360

页数：1

共 50 条

[1] Evaluation of the HAM-D17 following eszopiclone treatment in patients with insomnia co-morbid with major depressive disorder or generalized anxiety disorder
Montgomery, S.
Fava, M.
Krystal, A.
Wessel, T.
Amato, D.
Cooper, J.
McCall, W. V.
[J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 306 - 306
[2] Evaluation of the Hamilton depression scale following eszopiclone treatment for insomnia in patients with insomnia co-morbid with major depressive disorder or generalized anxiety disorder
Fava, M.
Pollack, M.
Rubens, R.
Amato, D.
Kostal, A.
Hayduk, R.
McCall, W.
[J]. SLEEP, 2007, 30 : A329 - A330
[3] Evaluation of the Hamilton depression scale following eszopiclone treatment for insomnia in patients with insomnia co-morbid with major depressive disorder or generalized anxiety disorder
Fava, Maurizio
Pollack, Mark
Rubens, Robert
Amato, David
Krystal, Andrew
Hayduk, Roza
McCall, W. Vaughn
[J]. BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 84S - 84S
[4] Insomnia severity in patients with primary insomnia and insomnia co-morbid with major depressive disorder or generalized anxiety disorder
Roth, Thomas
Wilson, Phebe
Schaefer, Kendyl
Pfleeger, Kimberly
Rubens, Robert
Fava, Maurizio
Pollack, Mark
[J]. BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 84S - 85S
[5] Relative effect sizes of eszopiclone treatment for insomnia in patients with primary insomnia and insomnia co-morbid with major depressive disorder, generalized anxiety disorder, perimenopausal transition or rheumatoid arthritis
Schaefer, K.
McCall, W.
Krystal, A.
Rubens, R.
Wilson, P.
Pfleeger, K.
Roth, T.
[J]. SLEEP, 2007, 30 : A243 - A244
[6] Baseline insomnia severity in patients with primary insomnia and insomnia co-morbid with major depressive disorder, generalized anxiety disorder, perimenopausal transition or rheumatoid arthritis
Roth, T.
Wilson, P.
Schaefer, K.
Rubens, R.
Walsh, J.
Krystal, A.
[J]. SLEEP, 2007, 30 : A247 - A247
[7] Sleep outcomes following eszopiclone discontinuation in patients with primary insomnia and insomnia co-existing with major depressive disorder or generalized anxiety disorder
Krystal, A.
Fava, M.
Pollack, M.
Rubens, R.
Schaefer, K.
Amato, D.
Roth, T.
[J]. SLEEP, 2007, 30 : A245 - A245
[8] Sleep outcomes following eszopiclone discontinuation in patients with primary insomnia co-existing with major depressive disorder or generalized anxiety disorder
Krystal, Andrew
Fava, Maurizio
Pollack, Mark
Rubens, Robert
Schaefer, Kendyl
Amato, David
Roth, Thomas
[J]. BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 84S - 84S
[9] Efficacy of venlafaxine and fluoxetine inpatients with major depressive disorder and co-morbid generalized anxiety disorder
Silverstone, PH
Salinas, EO
[J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2002, 17 : S81 - S81
[10] Differential sleep effects of eszopiclone treatment and discontinuation in patients with primary insomnia and insomnia co-existing with major depressive disorder or generalized anxiety disorder
Krystal, A.
Schaefer, K.
Rockett, C.
Fava, M.
Amato, D.
Roth, T.
[J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 306 - 306

← 1 2 3 4 5 →